Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
View corresponding page on italian website CURASEPT.IT
Home
Bleeding

BLEEDING GUMS: ACT ON THE CAUSES AND SYMPTOMS WITH CURASEPT MOUTHWASHES AND TOOTHPASTES

Bleeding gums is a symptom that should not be underestimated, often linked to a pathology: the most frequent are gingivitis and periodontitis, inflammations that affect the gums and periodontium respectively. It often occurs from an inflammatory condition in the mouth and is accompanied by the presence of reddened areas, swelling, edema and pain in the affected areas.

According to data from the Ministry of Health presented in theย Guidelines for the prevention of oral diseases,ย approximately 40-50% of the adult population suffers from gingivitis, a figure that rises to 60% if adolescents are also considered.

Ideally a product line will workย on both the symptoms and the cause.

 

Show more
Select a category...
curasept-ads-dna-gel-astringent-pro
CURASEPT ADS | DNA ASTRINGENT PRO GEL
curasept-ads-dna-oral-rinse-020-astringent-pro
CURASEPT ADS | DNA ASTRINGENT PRO ORAL RINSE
curasept-ads-dna-oral-toothpaste-astringent-pro
CURASEPT ADS | DNA ASTRINGENT PRO TOOTHPASTE

THE FIRST NON-STAINING CHLORHEXIDINE

The first Curasept mouthwashes and toothpastes with Chlorhexidine featuring A.D.S.ยฎย –ย Anti Discoloration System, an innovative, patented, and clinically tested system that reduces the appearance of yellow-brown spots on the teeth, which is the main side effect of Chlorhexidine.

A.D.S.ยฎย inhibits the two chemical reactions leading to pigmentation, without affecting the antiplaque activity of Chlorhexidine.ย 

Curasept ADS

small_c_popup.png

Vuoi accedere ai contenuti Extra? Registrati o fai Login per accedere ai contenuti a te dedicati: articoli, video ,schedeโ€ฆ e tanto altro!

Non ricordi la password?

Non sei registrato?
Clicca il pulsante qui sotto. La registrazione รจ gratuita.

Registrazione

Quality Policy

The Quality for CURASEPT S.p.A. is an essential condition to put itself successfully on the market, considering its characteristics and evolution.

The development of the Company and its profit are insured by the continuous search for quality towards excellence through the continuous improvement of its processes and the search for partners with quality systems adapted to our standards.

The Company aims to increase the customer satisfaction through the application of its Quality Management System, including the processes to improve the system and to ensure the compliance with the customer and applicable regulatory requirements.

For this purpose, the Company performs specific risks and opportunities assessment activities, connected to the context, stakeholders and related objectives, in order to identify the areas of system improvements and to define the appropriate actions for the risk control and mitigation and strengthening of its Quality System.

The starting point for the implementation of this policy is the pursuit of the following objectives:

  • Define and implement a Quality Management System according to 9001:2015+A1:2024 e UNI CEI EN ISO 13485:2021 regulation, as Manufacturer of Medical Devices;
  • Define and implement a system of procedures and operating instructions in harmony with the Directive 93/42/CEE, the Regulation (UE) 2017/745 and the Regulation (UE) 2023/607 for the applicable parts and subsequent changes and integrations, which satisfy the essential requirements set out in Annex I;
  • Define and implement a system of procedures in harmony with the Directive 2010/84, the Regulation 1235/2010, the Implementation Regulation n. 520/2012 and in accordance with the objectives of โ€œmodule I – โ€œGood Vigilance Practicesโ€ (GVP);
  • Establish and formalize the business organizational structure with the subdivision into areas of competences;
  • Clarify roles and responsibilities of business functions;
  • Define strategies and objectives and assign human and material resources for their achievement;
  • Define accurately business processes and related performance factors;
  • Ensure compliance with qualitative, quantitative and temporal requirements;
  • Constantly monitor the level of adequacy of the system with reference to regulations and laws;
  • Promote initiatives in order to improve the process of motivational and professional growth of human resources, considered as critical resources for future business developments;
  • Ensure the commitment to the satisfaction of requirements and the maintenance of effectiveness of the Quality Management System.

These objectives can be realized thanks to the involvement of the whole Company personnel.

In particular, the Managers of each Function provide their contribution so that the suggested improvements can be proposed to the General Direction, so that the Quality Policy can be a priority element in the choice of business qualitative and organizational strategies.

The involvement of the whole personnel in the improvement of internal and external processes should be aimed at reducing non-compliance and internal and external costs of non-quality; for this reason all employees should feel themselves committed in pursuing this policy.

Training courses, for all business levels, are promoted and planned by the General Direction in order to keep the personnel constantly up to date on the improvements performed for the processes.

The Quality Manual, which is distributed via the SistemaQualitร  to all process managers and the General Director, should represent a work tool for all Managers and their personnel for the implementation of the Quality Policy.

April 2025

General Direction